Vaccines for preventing rotavirus diarrhoea: vaccines in use (Q24203645)

2

0 references

Hanna Bergman

3

0 references

Irit Ben-Aharon

4

0 references

Sukrti Nagpal

5

0 references

Elad Goldberg

6

0 references

Femi Pitan

7

0 references

Nigel Cunliffe

Cochrane Database of Systematic Reviews

8

0 references

publication date

15 February 2012

0 references

published in

0 references

cites work

Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Immunogenicity of a human rotavirus vaccine (RIX4414) after storage at 37 °C for seven days

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: Randomised, double-blind, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

A short report on highlights of world-wide development of RIX4414: a Latin American experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Safety, Reactogenicity, and Immunogenicity of Human Rotavirus Vaccine RIX4414 in Human Immunodeficiency Virus-positive Infants in South Africa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Reductions in cross-neutralizing antibody responses in infants after attenuation of the human rotavirus vaccine candidate 89-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Rotavirus immunoglobulin a responses stimulated by each of 3 doses of a quadrivalent human/bovine reassortant rotavirus vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

The Effect of High‐Dose Vitamin A Supplementation Given with Bacille Calmette‐Guérin Vaccine at Birth on Infant Rotavirus Infection and Diarrhea: A Randomized Prospective Study from Guinea‐Bissau

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Acute infectious pediatric gastroenteritis: beyond oral rehydration therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

The future of rotavirus vaccines: a major setback leads to new opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Effectiveness of rotavirus vaccines for prevention of rotavirus gastroenteritis-associated hospitalizations in Israel: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

The human rotavirus vaccine RIX4414 in infants: a review of safety and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

A short report on clinical evaluation of RIX4414: highlights of world-wide development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes: integrated analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Coadministration of RIX4414 oral human rotavirus vaccine does not impact the immune response to antigens contained in routine infant vaccines in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Evaluation of circulating intestinally committed memory B cells in children vaccinated with attenuated human rotavirus vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

A short report on highlights of world-wide development of RIX4414: an European experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Pentavalent human-bovine reassortant rotavirus vaccine: a review of its efficacy and safety in preventing acute rotavirus gastroenteritis in healthy infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

The new pentavalent rotavirus vaccine composed of bovine (strain WC3) -human rotavirus reassortants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Evaluating the safety of a rotavirus vaccine: the REST of the story

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Rotavirus vaccine (RotaTeq).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Rotavirus live, oral, pentavalent vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Pentavalent human-bovine (WC3) reassortant rotavirus vaccine in special populations: a review of data from the Rotavirus Efficacy and Safety Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Rotavirus in Asia: the value of surveillance for informing decisions about the introduction of new vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Intussusception following rotavirus vaccine administration: Post-marketing surveillance in the National Immunization Program in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Rotavirus vaccine and diarrhea mortality: quantifying regional variation in effect size

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Selected regulatory and scientific topics for candidate rotavirus vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Diarrhea- and Rotavirus-Associated Hospitalizations Among Children Less Than 5 Years of Age: United States, 1997 and 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

The impact of rotavirus gastroenteritis on the family

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Options for the prevention of rotavirus disease other than vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

The effect of rotavirus vaccine on diarrhoea mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Global Illness and Deaths Caused by Rotavirus Disease in Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Oral rotavirus vaccines: how well will they work where they are needed most?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Effect of rotavirus vaccination on death from childhood diarrhea in Mexico

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Rotavirus vaccine--a powerful tool to combat deaths from diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

More on RotaShield and intussusception: the role of age at the time of vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Rotavirus vaccines against diarrhoeal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Rotavirus vaccine for preventing diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Vaccines for preventing rotavirus diarrhoea: vaccines in use

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Effect of Human Rotavirus Vaccine on Severe Diarrhea in African Infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Will pediatricians adopt the new rotavirus vaccine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Effectiveness of Monovalent Rotavirus Vaccine (Rotarix) against Severe Diarrhea Caused by Serotypically Unrelated G2P[4] Strains in Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

A short report on the highlights of world-wide development of RIX4414: a North American experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Prevention of Rotavirus Disease: Updated Guidelines for Use of Rotavirus Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Interpreting Results and Drawing Conclusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Efficacy of the Human Rotavirus Vaccine RIX4414 in Malnourished Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

Introduction to Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

Strategies for the development of a rotavirus vaccine against infantile diarrhea with an update on clinical trials of rotavirus vaccines.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

Introduction of human rotavirus vaccine in Latin America

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

A short report on highlights of worldwide development of RIX4414: a Singaporean experience

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

Effectiveness of Lanzhou lamb rotavirus vaccine against rotavirus gastroenteritis requiring hospitalization: a matched case-control study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

Rotavirus serotype G9 is associated with more-severe disease in Latin America

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

Rotavirus: the search for the next generation vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe: executive summary

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

Preventing rotavirus gastroenteritis: do you have the facts?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

Public health. Progress toward rotavirus vaccines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

Prevention of rotavirus disease: guidelines for use of rotavirus vaccine. American Academy of Pediatrics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

Efficacy of the pentavalent rotavirus vaccine in subjects after 1 or 2 doses in the rotavirus efficacy and safety trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021

Immunogenicity of a live-attenuated human rotavirus RIX4414 vaccine with or without buffering agent

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008521.PUB2

7 January 2021